Literature DB >> 2589483

Essential fatty acid deficiency during acute puromycin nephrosis ameliorates late renal injury.

J R Diamond1, I Pesek, S Ruggieri, M J Karnovsky.   

Abstract

Puromycin aminonucleoside (PA) nephrosis is associated with a significant increase in the glomerular macrophage number during peak proteinuria. The significance of this observation remains uncertain. An essential fatty acid-deficient (EFAD) diet depletes normal rat glomeruli of resident macrophages and alters glomerular eicosanoid metabolism. In this study, we found that an EFAD diet, administered only for the duration of the acute nephrotic phase, significantly ameliorated the recurrent albuminuria, renal dysfunction, and morphological injury characteristic of the late, recurrent phase of chronic aminonucleoside nephrosis. Glomerular macrophage number, isolated glomerular thromboxane B2 production, and circulating leukocyte and monocyte counts were significantly reduced in nephrotic rats on the EFAD diet 2 wk after PA injection, which temporally corresponds to peak albuminuria. The exact mechanism(s) by which the EFAD diet conferred protection in the late phase of chronic aminonucleoside nephrosis and lowered glomerular macrophage number during the acute nephrotic phase remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2589483     DOI: 10.1152/ajprenal.1989.257.5.F798

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  CXCL10 induces the recruitment of monocyte-derived macrophages into kidney, which aggravate puromycin aminonucleoside nephrosis.

Authors:  D Petrovic-Djergovic; M Popovic; S Chittiprol; H Cortado; R F Ransom; S Partida-Sánchez
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

Review 2.  An evaluation of experimental models of glomerulonephritis.

Authors:  P N Furness; K Harris
Journal:  Int J Exp Pathol       Date:  1994-02       Impact factor: 1.925

3.  Essential fatty acid deficiency ameliorates acute renal dysfunction in the rat after the administration of the aminonucleoside of puromycin.

Authors:  K P Harris; J B Lefkowith; S Klahr; G F Schreiner
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

4.  Gene expression of 5-lipoxygenase and LTA4 hydrolase in renal tissue of nephrotic syndrome patients.

Authors:  E Menegatti; D Roccatello; K Fadden; G Piccoli; G De Rosa; L M Sena; A Rifai
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

5.  Passive dual immunization against tumour necrosis factor-alpha (TNF-alpha) and IL-1 beta maximally ameliorates acute aminonucleoside nephrosis.

Authors:  A Martín; A Molina; T Bricio; F Mampaso
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

6.  Retinoids as a potential treatment for experimental puromycin-induced nephrosis.

Authors:  V Moreno-Manzano; F Mampaso; J C Sepúlveda-Muñoz; M Alique; S Chen; F N Ziyadeh; M C Iglesias-de la Cruz; J Rodríguez; E Nieto; J M Orellana; P Reyes; I Arribas; Q Xu; M Kitamura; F J Lucio Cazana
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

7.  Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis in rats.

Authors:  C L Jones; S Buch; M Post; L McCulloch; E Liu; A A Eddy
Journal:  Am J Pathol       Date:  1992-12       Impact factor: 4.307

8.  Glomerular macrophages and the mesangial proliferative response in the experimental nephrotic syndrome.

Authors:  J R Diamond; G Ding; J Frye; I P Diamond
Journal:  Am J Pathol       Date:  1992-10       Impact factor: 4.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.